CD8A and neoplasm: Moreover, in vivo results revealed that inhibition of DCLK1 increased the infiltration of CD8+ T cells (Figs. 3, 6), which suggested that DCLK1 inhibitor was conducive to alter immunologically cold tumor to immunologically hot tumor benefiting from immunotherapy.